Topical Administration of Pirfenidone Increases Healing of Chronic Diabetic Foot Ulcers: A Randomized Crossover Study


Por: Janka-Zires, M., Almeda-Valdes, P., Uribe-Wiechers, A.C., Juárez-Comboni, S.C., López-Gutiérrez, J., Escobar-Jiménez, J.J., Gómez-Pérez, F.J.

Publicada: 1 ene 2016
Resumen:
Only 30 percent of chronic diabetic foot ulcers heal after 20 weeks of standard treatment. Pirfenidone is a drug with biological, anti-inflammatory, and antifibrotic effects. The aim of this study was to evaluate the effect of topical pirfenidone added to conventional treatment in noninfected chronic diabetic foot ulcers. This was a randomized crossover study. Group 1 received topical pirfenidone plus conventional treatment for 8 weeks; after this period, they were switched to receive conventional treatment only for 8 more weeks. In group 2, the order of the treatments was the opposite. The end points were complete ulcer healing and size reduction. Final data were obtained from 35 ulcers in 24 patients. Fifty-two percent of ulcers treated with pirfenidone healed before 8 weeks versus 14.3% treated with conventional treatment only (P = 0.025). Between 8 and 16 weeks, 30.8% ulcers that received pirfenidone healed versus 0% with conventional treatment (P = 0.081). By week 8, the reduction in ulcer size was 100% [73-100] with pirfenidone versus 57.5% with conventional treatment [28.9-74] (P = 0.011). By week 16, the reduction was 93% [42.7-100] with pirfenidone and 21.8% [8-77.5] with conventional treatment (P = 0.050). The addition of topical pirfenidone to conventional treatment significantly improves the healing of chronic diabetic noninfected foot ulcers. © 2016 Marcela Janka-Zires et al.

Filiaciones:
Janka-Zires, M.:
 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Endocrinology and Metabolism Department, Vasco de Quiroga 15, Tlalpan, Mexico City, CDMX, Mexico

Almeda-Valdes, P.:
 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Endocrinology and Metabolism Department, Vasco de Quiroga 15, Tlalpan, Mexico City, CDMX, Mexico

Uribe-Wiechers, A.C.:
 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Endocrinology and Metabolism Department, Vasco de Quiroga 15, Tlalpan, Mexico City, CDMX, Mexico

Juárez-Comboni, S.C.:
 Grupo Ángeles, Camino a Santa Teresa 1055, Magdalena Contreras, Mexico City, CDMX, Mexico

López-Gutiérrez, J.:
 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Endocrinology and Metabolism Department, Vasco de Quiroga 15, Tlalpan, Mexico City, CDMX, Mexico

Escobar-Jiménez, J.J.:
 Cell Pharma, Calzada de Las Bombas 128, Mexico City, CDMX, Mexico

Gómez-Pérez, F.J.:
 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Endocrinology and Metabolism Department, Vasco de Quiroga 15, Tlalpan, Mexico City, CDMX, Mexico
ISSN: 23146745
Editorial
Hindawi Publishing Corporation, 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 2016 Número:
Páginas:
WOS Id: 000380318500001
ID de PubMed: 27478849